| Chronic Lymphocytic Leukemia
Copiktra vs Zydelig
Side-by-side clinical, coverage, and cost comparison for chronic lymphocytic leukemia.Deep comparison between: Copiktra vs Zydelig with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsZydelig has a higher rate of injection site reactions vs Copiktra based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Zydelig but not Copiktra, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Copiktra
Zydelig
At A Glance
Oral
Twice daily
PI3K-delta/gamma inhibitor
Oral
Twice daily
PI3K-delta inhibitor
Indications
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Chronic Lymphocytic Leukemia
Dosing
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma 25 mg orally twice daily in 28-day cycles; reduce to 15 mg twice daily for toxicity or when co-administered with strong CYP3A4 inhibitors; discontinue if unable to tolerate 15 mg twice daily.
Chronic Lymphocytic Leukemia 150 mg orally twice daily with or without food until disease progression or unacceptable toxicity; dose reductions to 100 mg twice daily apply after interruption for certain adverse reactions.
Contraindications
—
- History of serious hypersensitivity reactions to idelalisib, including anaphylaxis
- History of toxic epidermal necrolysis with any drug
Adverse Reactions
Most common (>=20%) Diarrhea or colitis, neutropenia, rash, fatigue, pyrexia, cough, nausea, upper respiratory infection, pneumonia, musculoskeletal pain, anemia
Serious Infection, diarrhea or colitis, pneumonia, rash, pneumonitis
Most common (>30%) Diarrhea, pneumonia, pyrexia, fatigue, rash, cough, nausea
Serious Hepatotoxicity, severe diarrhea or colitis, pneumonitis, infections (including sepsis, CMV, PJP), intestinal perforation, severe cutaneous reactions, hypersensitivity reactions, neutropenia
Postmarketing Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms
Pharmacology
Duvelisib is a PI3K-delta/gamma inhibitor that blocks B-cell receptor signaling and CXCR12-mediated chemotaxis of malignant B-cells, inducing growth inhibition and reduced viability in CLL tumor cells and malignant B-cell lines.
PI3K-delta inhibitor; idelalisib blocks BCR, CXCR4, and CXCR5 signaling pathways to induce apoptosis and inhibit proliferation in normal and malignant B-cells, and reduces chemotaxis and adhesion of lymphoma cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Copiktra
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (12/12)
Zydelig
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Copiktra
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Zydelig
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Copiktra
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Zydelig
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$5/momo
Secura Care Co-Pay Program: CopiktraCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
$5/momo
Zydelig Access Connect Copay Coupon CardCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CopiktraView full Copiktra profile
ZydeligView full Zydelig profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.